Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the task was to evaluate the effectiveness of prescribing small doses of quetiapine (25-75 mg) for bipolar patients in remission in order to relieve symptoms of impulsivity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal Stare Budgetary Scientific Institution, Mental Health Research Center
• Collaborators: Federal State Budgetary Institution V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, Saint-Petersburg, Russia; Kazan State Medical University
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

1. Availability of written informed consent to participate in the Program.

2. The established diagnosis of bipolar disorder in incomplete remission and the presence of violations in the field of impulse control (score on the Barratt scale above 70 points)

3. Age from 18 to 65 years inclusive;

4. The patient's desire and ability to participate in the study and follow the doctor's instructions.

Exclusion Criteria:

1. The presence of quetiapine intolerance in the anamnesis.

2. The presence of an actual active phase of bipolar disorder: depression (MADRS score above 22 points) or mania (YMRS score above 20 points).

3. Hypersensitivity to the components of quetiapine in the anamnesis;

4. Current clinically significant and unstable somatic diseases.

5. Participation in other observational programs or clinical trials during the conduct of this study.